logo
welcome
Reuters

Reuters

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue

Reuters
Summary
Nutrition label

81% Informative

Moderna cut 2024 sales forecast for COVID-19 and respiratory syncytial virus vaccines by up to 25% , or $1 billion .

Company had previously said it expected roughly $4 billion in sales for the year , which was already the lowest figure for annual revenue since it launched its COVID vaccine in late 2020 .

Moderna reported a net loss of $1.3 billion , or $ 3.33 per share, for the second quarter .

VR Score

92

Informative language

97

Neutral language

87

Article tone

formal

Language

English

Language complexity

47

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links